NO982590L - Metalloproteinase-inhibitorer, farmas°ytiske blandinger inneholdende dem og deres farmas°ytiske anvendelser, og fremgangsmÕter og mellomprodukter anvendelige for deres fremstilling - Google Patents

Metalloproteinase-inhibitorer, farmas°ytiske blandinger inneholdende dem og deres farmas°ytiske anvendelser, og fremgangsmÕter og mellomprodukter anvendelige for deres fremstilling

Info

Publication number
NO982590L
NO982590L NO982590A NO982590A NO982590L NO 982590 L NO982590 L NO 982590L NO 982590 A NO982590 A NO 982590A NO 982590 A NO982590 A NO 982590A NO 982590 L NO982590 L NO 982590L
Authority
NO
Norway
Prior art keywords
preparation
methods
intermediates useful
metalloproteinase inhibitors
pharmaceutical uses
Prior art date
Application number
NO982590A
Other languages
English (en)
Other versions
NO982590D0 (no
NO311360B1 (no
Inventor
Scott E Zook
Jr Raymond Dangnino
Michael E Deason
Steven L Bender
Michael J Melnick
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of NO982590D0 publication Critical patent/NO982590D0/no
Publication of NO982590L publication Critical patent/NO982590L/no
Publication of NO311360B1 publication Critical patent/NO311360B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO19982590A 1995-12-08 1998-06-05 Metalloproteinase-inhibitorer, farmasöytiske blandinger inneholdende dem og fremgangsmåter og mellomprodukter anvendeligefor deres fremstilling NO311360B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56976695A 1995-12-08 1995-12-08
PCT/US1996/019328 WO1997020824A1 (en) 1995-12-08 1996-12-05 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation

Publications (3)

Publication Number Publication Date
NO982590D0 NO982590D0 (no) 1998-06-05
NO982590L true NO982590L (no) 1998-08-05
NO311360B1 NO311360B1 (no) 2001-11-19

Family

ID=24276764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982590A NO311360B1 (no) 1995-12-08 1998-06-05 Metalloproteinase-inhibitorer, farmasöytiske blandinger inneholdende dem og fremgangsmåter og mellomprodukter anvendeligefor deres fremstilling

Country Status (39)

Country Link
US (1) US6153757A (no)
EP (2) EP1095936B1 (no)
JP (1) JP2000502330A (no)
KR (1) KR19990072009A (no)
CN (2) CN1542002A (no)
AP (2) AP1288A (no)
AT (2) ATE283264T1 (no)
AU (1) AU725831C (no)
BG (1) BG64279B1 (no)
BR (1) BR9611929A (no)
CA (1) CA2238306A1 (no)
CO (1) CO4790150A1 (no)
CZ (1) CZ292942B6 (no)
DE (2) DE69626684T2 (no)
DK (1) DK0874830T3 (no)
EA (1) EA003294B1 (no)
ES (2) ES2195034T3 (no)
GE (1) GEP20012388B (no)
GT (2) GT199700015AA (no)
HR (1) HRP970031A2 (no)
HU (1) HUP9902092A3 (no)
ID (1) ID17624A (no)
IL (6) IL138027A (no)
MX (1) MX9804457A (no)
MY (1) MY117290A (no)
NO (1) NO311360B1 (no)
NZ (1) NZ325559A (no)
OA (1) OA10794A (no)
PA (1) PA8431301A1 (no)
PE (1) PE69298A1 (no)
PL (1) PL327275A1 (no)
PT (1) PT874830E (no)
SI (1) SI0874830T1 (no)
SK (1) SK73898A3 (no)
SV (1) SV1997000008A (no)
TR (1) TR199800990T2 (no)
TW (1) TW546293B (no)
WO (1) WO1997020824A1 (no)
YU (1) YU21597A (no)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
ATE283264T1 (de) * 1995-12-08 2004-12-15 Agouron Pharma Zwischenprodukte zur herstellung von metallproteinasehemmern
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
NZ333824A (en) * 1996-07-22 2000-08-25 Monsanto Co Thiol sulfone metalloprotease inhibitors
DE69716934T2 (de) * 1996-08-28 2003-07-31 The Procter & Gamble Company, Cincinnati 1,3-diheterozyklische metalloprotease inhibitoren
DE69716615T2 (de) 1996-08-28 2003-06-18 The Procter & Gamble Company, Cincinnati Heterozyklische metalloproteaseinhibitoren
US6872742B2 (en) 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
RU2221782C2 (ru) 1996-08-28 2004-01-20 Дзе Проктер Энд Гэмбл Компани Замещенные циклические аминовые ингибиторы металлопротеаз
JP2000516252A (ja) * 1996-08-28 2000-12-05 ザ プロクター アンド ギャンブル カンパニー １，４―複素環式メタロプロテアーゼ阻害剤
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
WO1998016520A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
CA2275478A1 (en) 1996-12-17 1998-06-25 Kentaro Sato Piperazine compounds as inhibitors of mmp or tnf
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
EP0973392B1 (en) 1997-03-04 2003-11-19 Monsanto Company Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
EP0977745B1 (en) * 1997-03-04 2004-12-01 Pharmacia Corporation Thioaryl sulfonamide hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6087359A (en) * 1997-03-04 2000-07-11 Getman; Daniel P. Thioaryl sulfonamide hydroxamic acid compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
AU747280B2 (en) * 1997-04-01 2002-05-09 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2004137284A (ja) * 1997-06-17 2004-05-13 Kaken Pharmaceut Co Ltd ２−スルファモイル安息香酸誘導体
JP2001513484A (ja) 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
JPH11199512A (ja) * 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP2001523662A (ja) 1997-11-14 2001-11-27 ジー・ディー・サール・アンド・カンパニー 芳香族スルホンヒドロキサム酸メタロプロテアーゼ阻害剤
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP2002501056A (ja) * 1998-01-27 2002-01-15 アメリカン・サイアナミド・カンパニー マトリクス金属プロテイナーゼ阻害薬としての２，３，４，５−テトラヒドロ−１ｈ−［１，４］−ベンゾジアゼピン−３−ヒドロキサム酸
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
RU2208609C2 (ru) 1998-02-04 2003-07-20 Новартис Аг Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
CA2330108A1 (en) 1998-05-14 1999-11-18 Dupont Pharmaceuticals Company Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
JP2002518368A (ja) 1998-06-17 2002-06-25 デュポン ファーマシューティカルズ カンパニー メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類
EP0965592A1 (en) 1998-06-18 1999-12-22 F. Hoffmann-La Roche Ag Process for preparing 3-arylsulfur hydroxamic acids
FR2780402B1 (fr) 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
ATE297908T1 (de) * 1998-08-12 2005-07-15 Pfizer Prod Inc Tace inhibitoren
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
BR9914196A (pt) * 1998-09-30 2001-06-19 Procter & Gamble Processo de tratamento da perda de cabelo
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6288261B1 (en) * 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6858598B1 (en) * 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1140183A1 (en) * 1998-12-23 2001-10-10 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
SK11352001A3 (sk) 1999-02-08 2002-09-10 G. D. Searle & Co. Metaloproteázový inhibítor kyselina sulfamátohydroxámová
TR200102524T2 (tr) 1999-03-03 2002-02-21 The Procter & Gamble Company Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
HUP0202199A2 (en) 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
AUPP982399A0 (en) * 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
AR033651A1 (es) 1999-10-01 2004-01-07 Hoffmann La Roche Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
NZ521248A (en) 2000-03-17 2004-04-30 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
IL151018A0 (en) 2000-03-17 2003-02-12 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
JP4008708B2 (ja) * 2000-04-07 2007-11-14 サムスン エレクトロニクス カンパニー リミテッド マトリックスメタロプロテイナーゼの阻害剤としてのスルホンアミド誘導体
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
US6927216B2 (en) 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
US6642255B2 (en) 2001-01-11 2003-11-04 Bristol-Myers Squibb Pharma Company 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1355901A2 (en) 2001-01-11 2003-10-29 Bristol-Myers Squibb Pharma Company 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a)
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
AU2002258507A1 (en) 2001-03-15 2002-10-03 Bristol-Myers Squibb Company Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage)
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
WO2002092588A2 (en) 2001-05-11 2002-11-21 Pharmacia Corporation Aromatic sulfone hydroxamates and their use as protease inhibitors
JP2005500270A (ja) * 2001-05-29 2005-01-06 ギルフォード ファーマシュウティカルズ インコーポレイテッド 手術の結果として発生した神経損傷を治療するための方法
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
AUPR726201A0 (en) * 2001-08-24 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. New use of a cyclic compound
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
JP2005507937A (ja) 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイション マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
US6960567B2 (en) * 2001-11-30 2005-11-01 Bristol Myers Squibb Company Method of producing n-[(2S)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-L-leucyl-L-tert-leucine N-methylamide and intermediate thereof
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
JP2005537228A (ja) 2002-04-25 2005-12-08 ファルマシア・コーポレーション ピペリジニル−及びピペラジニル−スルホニルメチルヒドロキサム酸並びにプロテアーゼ阻害剤としてのその使用
AU2003233154A1 (en) 2002-06-10 2003-12-22 Pfizer Inc. Metabolites of prinomastat and their sythesis
CA2485346C (en) * 2002-06-12 2013-05-28 Exelixis, Inc. Human adam-10 inhibitors
AU2003277878A1 (en) * 2002-06-25 2004-01-06 Pharmacia Corporation Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
WO2004071390A2 (en) * 2003-02-14 2004-08-26 Applied Research Systems Ars Holding N.V. Piperazine-2-carboxamide derivatives
BRPI0407587A (pt) * 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
PL1608374T3 (pl) 2003-03-24 2009-08-31 Axikin Pharmaceuticals Inc 2-Fenoksy i 2-fenylosulfonoamidowe pochodne o aktywności antagonistycznej w stosunku do CCR3 do leczenia astmy i innych zaburzeń o podłożu zapalnym lub immunologicznym
GT200500139A (es) * 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
WO2009052200A2 (en) * 2007-10-16 2009-04-23 Symphony Evolution, Inc. Human adam-10 inhibitors
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
WO2011081884A1 (en) 2009-12-14 2011-07-07 Massachusetts Institute Of Technology Systems and methods related to optical nanosensors including photoluminescent nanostructures
IT1401253B1 (it) 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
WO2013050476A1 (en) * 2011-10-04 2013-04-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) New apoptosis inducing compounds
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas
WO2020218316A1 (ja) * 2019-04-26 2020-10-29 日産化学株式会社 アリールスルホン酸エステル化合物の製造方法
WO2020252439A1 (en) * 2019-06-14 2020-12-17 Loyola University Of Chicago Carborane hydroxamic acid matrix metalloproteinase agents for boron neutron capture therapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
WO1992009564A1 (en) * 1990-12-03 1992-06-11 Celltech Limited Peptidyl derivatives
WO1992021360A1 (en) * 1991-05-28 1992-12-10 Merck & Co., Inc. Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5376664A (en) * 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
JPH08503475A (ja) * 1992-11-25 1996-04-16 メルク エンド カンパニー インコーポレーテッド 抗変性活性剤としてのカルボキシ−ペプチジル誘導体
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
BR9407217A (pt) * 1993-08-05 1996-09-17 Syntex Inc Inibidores de metaloprotease de matriz
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
ES2139183T3 (es) * 1994-01-22 2000-02-01 British Biotech Pharm Inhibidores de las metaloproteinasas.
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
EP0763012B1 (en) * 1994-05-28 1999-06-09 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB2303850B (en) * 1994-06-22 1998-06-10 British Biotech Pharm Metalloproteinase inhibitors
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ATE198326T1 (de) * 1995-04-20 2001-01-15 Pfizer Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
US6022893A (en) * 1995-08-08 2000-02-08 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives
DE19542189A1 (de) * 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
KR100475206B1 (ko) * 1995-11-13 2005-12-16 훽스트 악티엔게젤샤프트 사이클릭및헤테로사이클릭N-치환된α-이미노하이드록삼산및카복실산
CZ291659B6 (cs) * 1995-11-17 2003-04-16 Warner-Lambert Company Sulfonamidové inhibitory matricových metaloproteináz
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
ATE283264T1 (de) * 1995-12-08 2004-12-15 Agouron Pharma Zwischenprodukte zur herstellung von metallproteinasehemmern
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
PT876343E (pt) * 1995-12-22 2002-08-30 Warner Lambert Co Ceto-acidos aromaticos e seus derivados como inibidores metaloproteinases de matriz
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
SK282995B6 (sk) * 1996-01-23 2003-01-09 Shionogi And Co., Ltd. Zlúčenina na inhibíciu metaloproteázy a prostriedok s jej obsahom
US6153609A (en) * 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
RU2221782C2 (ru) * 1996-08-28 2004-01-20 Дзе Проктер Энд Гэмбл Компани Замещенные циклические аминовые ингибиторы металлопротеаз
JP2000516252A (ja) * 1996-08-28 2000-12-05 ザ プロクター アンド ギャンブル カンパニー １，４―複素環式メタロプロテアーゼ阻害剤
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Also Published As

Publication number Publication date
US6153757A (en) 2000-11-28
BG102510A (en) 1999-08-31
CZ173398A3 (cs) 1998-11-11
EP1095936A1 (en) 2001-05-02
BR9611929A (pt) 1999-05-18
WO1997020824A1 (en) 1997-06-12
AU725831B2 (en) 2000-10-19
EA003294B1 (ru) 2003-04-24
CO4790150A1 (es) 1999-05-31
AP9801284A0 (en) 1998-09-30
SV1997000008A (es) 1999-02-15
NZ325559A (en) 2000-01-28
SI0874830T1 (en) 2003-08-31
TW546293B (en) 2003-08-11
CN1207734A (zh) 1999-02-10
IL138027A (en) 2004-08-31
CN1207289C (zh) 2005-06-22
SK73898A3 (en) 1999-01-11
HUP9902092A3 (en) 2000-12-28
IL143674A0 (en) 2002-04-21
HUP9902092A2 (hu) 1999-09-28
GT199700015AA (es) 1998-07-23
IL134816A (en) 2003-02-12
IL138028A0 (en) 2001-10-31
EP0874830B1 (en) 2003-03-12
KR19990072009A (ko) 1999-09-27
BG64279B1 (bg) 2004-08-31
EA199800541A1 (ru) 1998-12-24
AP1368A (en) 2005-04-21
AU1409197A (en) 1997-06-27
CN1542002A (zh) 2004-11-03
CA2238306A1 (en) 1997-06-12
ID17624A (id) 1998-01-15
EP1095936B1 (en) 2004-11-24
ES2233275T3 (es) 2005-06-16
CZ292942B6 (cs) 2004-01-14
IL134816A0 (en) 2001-05-20
MY117290A (en) 2004-06-30
NO982590D0 (no) 1998-06-05
OA10794A (en) 2001-07-05
MX9804457A (es) 1998-09-30
GEP20012388B (en) 2001-03-25
AP1288A (en) 2004-07-21
PL327275A1 (en) 1998-12-07
ATE283264T1 (de) 2004-12-15
GT199700015A (es) 1998-07-23
HRP970031A2 (en) 1998-08-31
IL124559A (en) 2004-07-25
YU21597A (en) 1999-11-22
PT874830E (pt) 2003-06-30
DE69626684D1 (de) 2003-04-17
ATE234291T1 (de) 2003-03-15
DE69633947T2 (de) 2005-12-01
AP2001002270A0 (en) 2001-09-30
NO311360B1 (no) 2001-11-19
PA8431301A1 (es) 2000-05-24
JP2000502330A (ja) 2000-02-29
TR199800990T2 (xx) 1998-07-21
DE69626684T2 (de) 2004-04-29
DE69633947D1 (de) 2004-12-30
AU725831C (en) 2002-10-17
IL138027A0 (en) 2001-10-31
IL124559A0 (en) 1998-12-06
DK0874830T3 (da) 2003-04-22
EP0874830A1 (en) 1998-11-04
PE69298A1 (es) 1998-11-13
ES2195034T3 (es) 2003-12-01

Similar Documents

Publication Publication Date Title
NO982590L (no) Metalloproteinase-inhibitorer, farmas°ytiske blandinger inneholdende dem og deres farmas°ytiske anvendelser, og fremgangsmÕter og mellomprodukter anvendelige for deres fremstilling
FI973278A (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
NO974335D0 (no) Laktam-holdige hydroksaminsyrederivater, deres fremstilling og deres anvendelse som inhibitorer for matriksmetallprotease
DK0876332T3 (da) Phenyleddikesyrederivater, fremgangsmåde og mellemprodukter til deres fremstilling og midler indeholdende disse
DK0676409T3 (da) Erythromycinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
DK1156049T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1017670T3 (da) Benzamidoximderivater, mellemprodukter og fremgangsmåder til deres fremstilling og deres anvendelse som fungicider
NO962527L (no) Naftalenderivater, fremgangsmåter for deres fremstilling og mellomprodukter for dem
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
IS1960B (is) Lyfjafræðileg blanda N-Píperídínó-3-pýrazólkarboxamíð afleiðum, söltum og lausnarsamböndum til munnlegrar inntöku
NO964654D0 (no) Nye erytromycinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler
DK157592D0 (da) Dualinhibitorer for no synthese og cyclooxygenase, fremgangsmaade til deres fremstilling og farmaceutiske praeparater indeholdende disse
FI973279A (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
DK0835246T3 (da) Aromatiske forbindelser og farmaceutiske præparater, der indeholder dem
DK0885234T3 (da) Nye erythromycinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
NO20000294D0 (no) Derivater av acylpiperazinylpyrimidiner, deres fremstilling og anvendelse som legemidler
DK0885204T3 (da) Nye arylglycinamidderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse forbindelser
NO932120D0 (no) Bifenylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
NO985671D0 (no) Nye Tiazolidindion-2-derivater som er 4-diketonsubstituerte, fremgangsmÕte for deres fremstilling og farmas°ytiske preparater som inneholder dem
NO952677D0 (no) Nye dihydropyrrolopyridinon- og oksazolopyridinonforbindelser, deres fremstilling og farmasöytiske preparater
NO984290L (no) Farmas°ytisk nyttige forbindelser
DK1095020T3 (da) 2-Aminopyridinderivater, deres anvendelse som lægemidler og farmaceutiske præparater, der indeholder dem
NO984309D0 (no) Nye imidazolidinderivater, deres fremstilling, deres anvendelse og farmas°ytiske preparater inneholdende disse
DK1015421T3 (da) Nye phenylamidinderivater, fremgangsmåder til deres fremstilling og deres anvendelse som lægemidler
NO994659D0 (no) Nye pyridinderivater og farmasöytiske preparater inneholdende slike